Sign Out
Seasonal Allergic or Perennial Rhinitis: After initial priming of Nasonex aqueous nasal spray (usually 6 or 7 actuations until a uniform spray is released), each actuation delivers approximately 100 mg of mometasone furoate suspension, containing mometasone furoate monohydrate equivalent to mometasone furoate 50 mcg. Prior to administration of the 1st dose, shake container well and actuate pump well before each use. If Nasonex has not been used for 14 days or longer, it should be reprimed before next use.
Adults (Including the Elderly) and Children ≥12 years: The usual recommended dose for prophylaxis and treatment, 2 sprays (50 mcg/spray) in each nostril once daily (total dose 200 mcg). Once symptoms are controlled, dose reduction to 1 spray in each nostril (total dose 100 mcg) may be effective for maintenance.
If symptoms are inadequately controlled, the dose may be increased to a maximum daily dose of 4 sprays in each nostril once daily (total dose 400 mcg). Dose reduction is recommended following control of symptoms.
Children 2-11 years: The usual recommended dose is 1 spray (50 mcg/spray) in each nostril once daily (total dose 100 mcg).
Administration to young children should be aided by an adult.
Nasonex aqueous nasal spray demonstrates a clinically significant onset of action within 12 hrs after the 1st dose in some patients with seasonal allergic rhinitis; this was also shown in a clinical trial with Nasonex aqueous nasal spray. However, full benefit of treatment may not be achieved in the first 48 hrs. Therefore, the patient should continue regular use to achieve full therapeutic benefit.
